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Background: Alcohol is a well-known risk factor for hepatocellular carcinoma (HCC), but the mechanisms underlying the
alcohol-related hepatocarcinogenesis are still poorly understood. Alcohol alters the provision of methyl groups within the
hepatic one-carbon metabolism, possibly inducing aberrant DNA methylation. Whether specific pathways are
epigenetically regulated in alcohol-associated HCC is, however, unknown. The aim of the present study was to
investigate the genome-wide promoter DNA methylation and gene expression profiles in non-viral, alcohol-associated
HCC. From eight HCC patients undergoing curative surgery, array-based DNA methylation and gene expression data of
all annotated genes were analyzed by comparing HCC tissue and homologous cancer-free liver tissue.
Results: After merging the DNA methylation with gene expression data, we identified 159 hypermethylated-repressed,
30 hypomethylated-induced, 49 hypermethylated-induced, and 56 hypomethylated-repressed genes. Notably,
promoter DNA methylation emerged as a novel regulatory mechanism for the transcriptional repression of genes
controlling the retinol metabolism (ADH1A, ADH1B, ADH6, CYP3A43, CYP4A22, RDH16), iron homeostasis (HAMP),
one-carbon metabolism (SHMT1), and genes with a putative, newly identified function as tumor suppressors
(FAM107A, IGFALS, MT1G, MT1H, RNF180).
Conclusions: A genome-wide DNA methylation approach merged with array-based gene expression profiles allowed
identifying a number of novel, epigenetically regulated candidate tumor-suppressor genes in alcohol-associated
hepatocarcinogenesis. Retinol metabolism genes and SHMT1 are also epigenetically regulated through promoter
DNA methylation in alcohol-associated HCC.
Due to the reversibility of epigenetic mechanisms by environmental/nutritional factors, these findings may open
up to novel interventional strategies for hepatocarcinogenesis prevention in HCC related to alcohol, a modifiable
dietary component.
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Chronic alcohol consumption is one of the main etiological
factors of hepatocellular carcinoma (HCC) [1]. The mecha-
nisms by which ethanol promotes liver carcinogenesis are
still not completely known, but alcohol is recognized inter-
fering with several pathways including that of acetaldehyde,
the first metabolic product of ethanol oxidation, that
acts as a carcinogen [2]. Ethanol also affects one-
carbon metabolism by altering the provision of methyl
groups for biological methylation reactions, therefore
proposing the alteration of methylation of DNA as
a possible underlying mechanism for the alcohol-
mediated carcinogenesis [3]. DNA methylation is
catalyzed by DNA methyltransferases through the transfer
of one-carbon units from S-adenosylmethionine (AdoMet)
to the 5′ carbon of cytosines at CpG sequences in pro-
moter and gene regulatory regions [4]. DNA methyla-
tion is the main epigenetic feature of DNA with a main
function in gene transcriptional regulation as well as
preservation of genome stability, and a wide variety of
malignancies are characterized by aberrancies in DNA
methylation [4,5]. Both a global DNA hypomethylation
has been described as an almost universal finding in
cancer [6,7], and a concurrent gene-specific hypermethyla-
tion has been observed at specific tumor-suppressor gene
sites [7,8].
In a rodent model of HCC induced by methyl-
deficient diet, DNA methylation was abnormally regu-
lated [9]. Since alcohol exposure exerts effects that are
similar to those induced by a methyl-deficient diet, it
appears of interest to analyze the alcohol-induced
epigenetic modifications, with the aim to shed light
on alcohol-associated hepatocarcinogenesis. Alcohol is
therefore both a major carcinogenic trigger and a factor
altering one-carbon metabolism [10]. Considering the








1 66 >20 yes A6 Neg Neg
2 70 6 yes A5 Neg Neg
3 66 16 yes A5 Neg Neg
4 82 11 yes A5 Neg Neg
5 68 5 no A5 Neg Neg
6 60 6 yes A5 Neg Neg
7 75 4 yes A5 Neg Neg
8 71 10 yes A5 Neg Neg
a1 unit is defined as 12 g of ethanol = 125-ml wine or 330-ml beer or 40-ml spirit.
Abbreviations: HBV Ag, hepatitis B virus antigen ; HCVAb, hepatitis C virus antibody
fraction A; GGT, gamma-glutamyl transpeptidase; CHE, cholinesterase; AST, aspartat
Alcohol drinking defined as ≥36 g ethanol/day for males and ≥24 g ethanol/day for
Reference values: Hb (g/dl) 13.5 to 16; MCV (fl) 86 to 98; IgA (g/L) 0.7 to 4.0; GG
aFP (mg/L) <7.nutritional factors such as alcohol intake [3], it is of
particular interest to evaluate profiles of DNA methylation
in alcohol-related HCC. Previous studies evaluating DNA
methylation signature of HCC have mainly focused on
HCC of viral etiology [11,12]. DNA methylation mecha-
nisms could be more involved in hepatocarcinogenesis as-
sociated with alcohol, chronic consumption of which is
known to significantly alter DNA methylation [3], relative
to viral hepatocarcinogenesis in which genetic mechanisms
have been extensively explored.
The aim of the present study was to define promoter
DNA methylation and gene expression profiles in HCC
tissues compared to homologous cancer-free liver tis-
sues, by genome-wide, array-based approaches with the
purpose of identifying possible novel epigenetically
regulated pathways in alcohol-associated HCC.
Results
Clinical characteristics of HCC patients
The main clinical and biochemical characteristics of the
patients are described in Table 1. Patients were males
with an age ranging from 60 to 82 years. All of them
were habitual drinkers for a period ≥20 years with a daily
alcohol intake ≥3 units. The assessment of stage Child-
Pugh score A, normal transaminases and GGT con-
firmed the absence of decompensate liver disease.
Hematologic tests did not show abnormalities. IgA was
also within the normal range. As expected, due to selec-
tion criteria, viral serologic tests for HBV and HCV were
negative. Alphafetoprotein was higher than normal in all
but one patient (Table 1).
Promoter methylation profiles in HCC versus cancer-free
tissues
The MeDIP-chip analysis showed 2,399 hypermethylated

















12.1 88.0 2.22 67 4,138 25 57 5,871
12.0 69.1 0.91 32 4,606 23 37 411
15.6 89.9 4.08 48 4,624 30 33 967
11.2 88.8 1.66 43 7,353 29 28 62
16.0 98.1 3.98 52 7,856 25 29 190
13.8 98.6 1.60 223 3,564 38 51 5
13.7 90.3 3.28 30 7,225 28 15 431
13.3 91.4 1.56 88 8,430 24 29 21
; Hb, hemoglobin; MCV, mean corpuscolar volume; IgA, immunoglobulin
e transaminase; ALT, alanine transaminase; aFP, alphafetoprotein.
females.
T (U/l) <50; CHE (U/l) 4,650 to 14,400; AST (U/l) 8 to 50; ALT (U/l) 8 to 45;
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compared to cancer-free tissues. The differentially meth-
ylated genes are represented by a HeatMap in Figure 1.
The PANTHER classification system identified a large
number of differentially methylated genes belonging to
pathways involved in carcinogenesis as apoptosis, cell
communication and adhesion, cell cycle regulation, and
immune system (Figure 1) (see complete data in Additional
file 1: Table S1 and in Additional file 2: Table S2).
Gene expression in HCC versus cancer-free tissues
The array-based analysis of gene expression of HCC versus
cancer-free tissue showed 1,004 downregulated and 668 up-
regulated genes (see complete set in Additional file 3:
Table S3 and in Additional file 4: Table S4). Among the
repressed genes, several pertain to retinol metabolism
(ADH1A, ADH1B, ADH6, CYP1A1, CYP1A2, CYP2B6,
CYP2C9, CYP26A1, CYP3A4, CYP3A43, CYP4A11, CYP
4A22, RDH16, RDH5, LRAT, ALDH1A3, ALDH8A1, BCO2)
and to one-carbon metabolism (BHMT1, BHMT2, CBS,
GNMT, MTHFD2L, CTH, SDS, SHMT1).
Promoter DNA methylation profile according to array-
based gene expression in HCC versus cancer-free tissues
The promoter DNA methylation was merged with the
array-based gene expression data in HCC versus cancer-
free tissues. The analysis allowed distinguishing four
groups of genes, according to the status of both pro-
moter DNA methylation and gene expression. Such
analysis highlighted 159 hypermethylated-repressed, 30
hypomethylated-induced, 49 hypermethylated-induced,
and 56 hypomethylated-repressed genes.Figure 1 HeatMap of hypermethylated and hypomethylated genes by Me
values between HCC and cancer-free tissues. The chromatic scale (left side)
+0.10 (red, hypermethylated in HCC). Bar chart (right side) representation o
by PANTHER classification system according to biological processes.Hypermethylated-repressed genes
Table 2 shows the list of hypermethylated-repressed
genes subdivided according to their biological function
by means of PANTHER classification system. Twenty-
six genes involved in cell cycle, growth, proliferation,
and apoptosis. Five genes (FAM107A, IGFALS, MT1G,
MT1H, RNF180) were highly methylated in the pro-
moter region. Forty-three of those hypermethylated-
repressed genes pertain to cellular processes regulation
and six to retinol metabolism (ADH1A, ADH1B, ADH6,
CYP3A43, CYP4A22, RDH16). A key gene of one-carbon
metabolism, serine hydroxymethyltransferase 1 (SHMT1),
involved in the methyl groups formation and transfer reac-
tions also clustered in this group (Table 2). Further 23
genes involved in immune response clustered within this
group among which hepcidin (HAMP), a molecule with
hormone functions that controls the absorption of dietary
iron and its distribution in different cells.
Hypomethylated-induced genes
Thirty genes belonged to this group (Table 3) among
which: NADPH oxidase 4 (NOX4), linked to the production
of various reactive oxygen species; the serine protease in-
hibitor, Kazal-type 1 (SPINK1), known as tumor-associated
trypsin inhibitor (TATI) and endothelial cell-specific mol-
ecule 1 (ESM1), involved in angiogenesis.
Hypermethylated-induced and hypomethylated-repressed
genes
Among the 49 hypermethylated-induced genes (Table 4)
clustered, the matrix metallopeptidase 9 (MMP9) and 12
(MMP12) were involved in the breakdown of extracellularDIP-chip analysis. The figure shows the differences in DNA methylation
represents values from −0.10 (green, hypomethylated in HCC) to
f hypermethylated (red) and hypomethylated (green) genes clustered
Table 2 Hypermethylated and transcriptionally repressed genes (n = 159) in HCC as compared to cancer-free tissue
Cell communication (17)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
AKAP2 0.014 −1.5 INHBC 0.003 −1.4 RND3 0.002 −2.3
AMHR2 0.019 −1.4 MORN4 0.025 −1.2 SH3D19 0.004 −1.2
BZRAP1 0.039 −1.0 OLFML3 0.015 −2.3 SORBS2 0.013 −1.1
C1orf168 0.009 −1.5 PDE2A 0.011 −1.7 SUCNR1 0.006 −1.8
CLDN1 0.003 −1.0 PPL 0.01 −1.6 VNN1 0.031 −1.5
FES 0.00001 −1.5 RIC3 0.004 −1.8
Immune response (23)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
ANTXR2 0.012 −1.4 CFI 0.009 −1.0 KLKB1 0.007 −1.8
BLNK 0.002 −1.0 CFP 0.00002 −3.3 LILRA1 0.007 −1.2
C1QTNF1 0.035 −2.3 FCGR2B 0.047 −1.2 MBL2 0.046 −1.9
C1RL 0.016 −1.0 FCN2 0.00001 −3.7 MEFV 0.01 −1.4
C5AR1 0.037 −1.1 HAMP 0.01 −3.4 PGLYRP2 0.001 −1.9
CCL14 0.029 −1.5 IL13RA2 0.00001 −3.8 TINAGL1 0.043 −1.3
CCL15 0.029 −1.5 IL1B 0.005 −1.8 VSIG4 0.025 −2.4
CD302 0.003 −1.2 IL1RN 0.007 −1.1
Transport (19)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
ANXA8 0.043 −2.4 SLC10A1 0.019 −2.2 SLC5A1 0.012 −3.2
APOA5 0.004 −1.7 SLC22A1 0.002 −2.1 SLC6A12 0.007 −1.7
APOL6 0.005 −1.5 SLC22A10 0.009 −2.5 SLCO1B3 0.012 −3.7
AQP7 0.041 −1.0 SLC25A25 0.045 −1.3 SLCO2B1 0.001 −1.4
CETP 0.00001 −3.2 SLC25A47 0.011 −2.0 TRPV4 0.005 −2.1
MIP 0.006 −1.0 SLC45A3 0.012 −1.2
RGN 0.009 −1.7 SLC47A1 0.033 −1.2
Metabolic and cellular process (43)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
ACADS 0.002 −1.3 FBXO3 0.004 −1.3 MOGAT2 0.00001 −3.2
ACSM5 0.026 −1.0 FMO3 0.019 −1.0 OAT 0.046 −2.0
AGMO 0.028 −1.3 GLUD2 0.004 −1.3 PLIN 0.012 −1.8
AMDHD1 0.048 −1.1 GPT 0.009 −1.0 PSD4 0.002 −1.2
ANK2 0.019 −1.0 GYS2 0.005 −3.0 TBXA2R 0.0004 −1.3
ANK3 0.026 −1.8 HGFAC 0.033 −3.1 UROC1 0.014 −2.5
ARSD 0.022 −1.4 HK3 0.003 −1.3 Retinol metabolism
ATP11C 0.047 −1.0 HOGA1 0.002 −1.8 ADH1A 0.021 −1.4
BCO2 0.007 −3.1 IDO2 0.002 −3.7 ADH1B 0.021 −1.4
CES4A 0.023 −1.2 INMT 0.021 −1.2 ADH6 0.016 −1.9
CHST9 0.026 −1.5 IYD 0.003 −1.8 CYP3A43 0.027 −2.2
CPN1 0.014 −1.1 KDM5D 0.048 −1.5 CYP4A22 0.02 −1.1
CYP8B1 0.005 −2.7 LCAT 0.001 −1.8 RDH16 0.024 −1.4
DSE 0.022 −1.3 LDHD 0.018 −1.1 One-carbon metabolism
EPHX2 0.025 −1.1 LPAL2 0.003 −1.4 SHMT1 0.003 −1.1
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Table 2 Hypermethylated and transcriptionally repressed genes (n = 159) in HCC as compared to cancer-free tissue
(Continued)
Cell growth, cell cycle and apoptosis (26)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
ADORA3 0.014 −1.9 GDF2 0.00002 −2.7 TBX15 0.019 −1.7
AGTR1 0.006 −1.5 JDP2 0.007 −1.1 TNFRSF10D 0.025 −1.2
AR 0.038 −1.4 MAP2K3 0.007 −1.1 ZBED1 0.003 −1.1
AXL 0.049 −1.5 NAP1L5 0.004 −1.1 Candidate tumor-suppressor genes
CAT 0.006 −1.1 NR4A1 0.043 −1.3 FAM107A 0.018 −1.3
DBH 0.002 −2.7 NUGGC 0.001 −1.8 IGFALS 0.00005 −3.2
DMD 0.043 −1.2 PTH1R 0.006 −2.5 MT1G 0.002 −2.8
ESR1 0.002 −3.0 PTPN3 0.001 −1.2 MT1H 0.004 −1.6
FGD4 0.01 −1.1 SMAD6 0.001 −1.3 RNF180 0.021 −1.2
Miscellaneous (31)a
Gene Name P value Coefficient Gene Name P value Coefficient Gene Name P value Coefficient
ADAMTSL2 0.04 −2.1 FAM13A 0.037 −1.6 PID1 0.019 −1.1
ALPL 0.003 −1.4 FAM65C 0.001 −1.4 PRSS53 0.026 −1.1
ANKRD55 0.001 −1.6 FAM83F 0.002 −1.4 SMOC1 0.015 −1.2
C10orf26 0.0001 −1.3 FXYD7 0.021 −1.1 SPATA18 0.005 −2.6
C10orf58 0.01 −1.2 HAPLN4 0.027 −1.6 SYNE1 0.021 −1.1
C17orf91 0.003 −1.2 INS-IGF2 0.0002 −4.2 TCTEX1D1 0.023 −1.3
C21orf84 0.04 −1.6 LINC00574 0.008 −1.1 TMEM125 0.039 −1.3
CCDC68 0.002 −1.6 LOC339240 0.014 −1.9 TMEM26 0.025 −1.2
CILP 0.0001 −2.1 LRRC25 0.039 −1.3 UNC93A 0.04 −1.2
DNALI1 0.003 −1.8 MYO15A 0.007 −1.2 WDR66 0.0001 −2.1
EXPH5 0.017 −2.3
aNumber of genes hypermethylated and transcriptionally repressed. Coefficient and P value refer to gene expression data.
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tosis. Among the 56 hypomethylated-repressed genes
(Table 5), two candidate tumor-suppressor genes were
identified, the hepatic and glial cell adhesion molecule
(HEPACAM) and the ABI family, member 3 (NESH) bind-
ing protein (ABI3BP).
Validation of array-based methylation and expression data
MeDIP-chip analysis was validated by direct bisulfite se-
quencing of three hypermethylated (ESR1, RDH16, and
SHMT1) and one hypomethylated (ESM1) gene. The
sequencing analysis thoroughly confirmed the methyla-
tion differences between HCC and cancer-free tissue
achieved by the high-throughput technique (Additional
file 5: Figure S1). The validation of array-based expres-
sion data by RealTime RT-PCR was performed on seven
repressed genes (ADH6, BCO2, ESR1, GDF2, HAMP,
RDH16, SHMT1) and four induced genes (DNMT3B,
ESM1, NOX4, SPINK1), and all the outcomes fully sup-
ported the results obtained by the array (Additional file
6: Figure S2).Discussion
DNA methylation is the main epigenetic mechanism of
gene expression regulation in humans, and alterations of
this mechanism are regarded among the major molecu-
lar aberrations in malignancies [4,5]. The etiologic role
of alcohol in hepatocarcinogenesis is well known [3],
although the mechanisms underlying the link between
alcohol and HCC are yet not completely defined [3]. In-
creasing evidence claims the importance of epigenetic
features in alcohol-associated disorders including cancer
[3] where appears crucial the effects of ethanol on one-
carbon metabolism, ultimately leading toward an altered
provision of methyl groups for methylation reactions
[13] including those of DNA and histone proteins.
Alcohol interferes with key enzymes in one-carbon
metabolism and eventually causes impaired AdoMet
levels [13] and inhibition of DNA methyltransferases
by S-adenosylhomocysteine (AdoHcy) [14,15]. It is,
therefore, likely to hypothesize that alcohol acts via
aberrant DNA methylation for carcinogenesis [16].
Chronic alcohol consumption has been demonstrated
Table 3 Hypomethylated and transcriptionally induced
genes (n = 30) in HCC as compared to cancer-free tissue
Cell communication (6)a
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KIF4A 0.006 2.2
SLC7A11 0.006 2.6
Metabolic and cellular process (3)a
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aNumber of genes hypermethylated and transcriptionally repressed.
Coefficient and P value refer to gene expression data.
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in rodent models [15]. Furthermore, in cystathionine-beta-
synthase deficiency mouse model exposed to high ethanol
feeding, the altered methionine metabolism caused modifi-
cations both in DNA [18] and histone methylation profiles
[19] while there is very little evidence for the effects of alco-
hol on epigenetic mechanisms in humans, thus far. In the
present investigation, promoter DNA methylation and gene
expression profiling were assessed at 22,532 promoter sites
by genome-wide, array-based techniques in paired human
HCC tissue compared to surrounding cancer-free liver tis-
sue, after excluding the major known etiologic factors for
HCC except a history of significant chronic alcohol intake.
Previous studies evaluated the methylation signatures in
HCC by a similar genome-wide approach and by evaluating
tumor versus adjacent non-tumor tissues [11,12,20,21].
They differed for study design and enrolment criteria as for
HCC etiologies [11,12,20,21] and for the purpose of either
evaluating predictive HCC markers [11,20] or for the scope
of identifying DNA methylation patterns specifically associ-
ated with disease progression [21].
All of the patients enrolled in this study were selected
precisely to exclude HCC of viral etiology and for the
absence of a severe liver derangement according to the
Child-Pugh score.
By comparing the methylation profile of cancer versus
homologous cancer-free liver tissues, 2,399 hypermethy-
lated and 1,243 hypomethylated genes were identified in
neoplastic tissue (Additional file 1: Table S1 and Additional
file 2: Table S2). The differentially methylated genes, both
hyper- and hypomethylated, represent an epigenetic peculi-
arity of alcohol-related HCC and may deserve future stud-
ies to identify new possible epigenetic markers of this
specific type of cancer. In particular, the methylation status
of specific genes has been proposed as a non-invasive
tumor marker for HCC, by the analysis of circulating DNA
derived from tumor cells [12,22]. In the field of DNA
methylation, this technique represents a new and promising
application that needs to be further explored. The aim of
this study was to evaluate the role of promoter DNA
methylation at gene transcriptional levels, then the pro-
moter methylation patterns were merged with gene
expression profiles allowing the identification of four
groups of genes, being hyper- or hypomethylated and
either repressed or induced in terms of gene expres-
sion. Only few studies evaluated the promoter methy-
lation and gene expression profiling in HCC [23,24]
and none yet in alcohol-related HCC. Among the
cluster of hypermethylated-transcriptionally repressed
genes (Table 2), five genes were identified as of poten-
tial interest for HCC, that is, FAM107A, RNF180,
MT1H, MT1G, IGFALS. Although FAM107A, RNF180,
and MT1H have been previously described for their
implication in cancer affecting other tissues [25-27],
Table 4 Hypermethylated and transcriptionally induced
genes (n = 49) in HCC as compared to cancer-free tissue
Cell communication (7)a
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aNumber of genes hypermethylated and transcriptionally repressed.
Coefficient and P value refer to gene expression data.
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was previously unknown for a possible association
with HCC.
FAM107A was described in renal cell carcinoma as a
putative tumor-suppressor gene according to its role in
the regulation of apoptotic processes [25,28]. Reports on
RNF180 are scarce, though this gene was recently char-
acterized as hypermethylated and silenced in gastric can-
cer [27] with a potential function in apoptosis [27]. As
for MT1H and MT1G, it is known that metallothioneins
(MTs) represent a class of proteins involved in processes
of cellular detoxification from ROS and heavy metals
and, through this mechanism, they might act as tumor-
suppressor genes [29]. The methylation-mediated re-
pression of MT1G has already been described in HCC
[23] and hepatoblastoma in children [30]. The MT1H,
another gene of the metallothionein family, from results
of the present study is transcriptionally downregulated
by promoter hypermethylation. Our results also confirm
previous findings showing IGFALS as a possible tumor-
suppressor gene silenced by methylation in HCC [23,24].
While it is not possible, from the present results, to
define that the hypermethylated-repressed genes have a def-
inite role as tumor suppressors, a hypothesis can be formu-
lated in this regard, although it certainly needs further
investigation. The largest number of hypermethylated-
repressed genes was clustered in the category of metabolic
and cellular processes (Table 2). Interestingly, the analysis
Table 5 Hypomethylated and transcriptionally repressed
genes (n = 56) in HCC as compared to cancer-free tissue
Cell communication (8)a
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aNumber of genes hypermethylated and transcriptionally repressed.
Coefficient and P value refer to gene expression data.
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metabolism, that is, ADH1A, ADH1B, ADH6, CYP3A43,
CYP4A22, and RDH16. Retinoid compounds, namely
vitamin A and its derivatives, are known to be in-
volved in the regulation of cellular growth, cellular dif-
ferentiation, and apoptosis, and chronic ethanol intake
was described to impair retinoic acid homeostasis in
the development of alcohol-related cancers [31]. The
present results suggest that the downregulation of
those genes by DNA methylation may be among the
mechanisms responsible for the derangement of ret-
inol metabolism associated to chronic alcohol con-
sumption. Interestingly, results from the present study
show also a SHMT1 gene repression by promoter
hypermethylation. SHMT1 is a key gene within one-
carbon metabolism that operates as a metabolic switch
between nucleotide synthesis and biological methyla-
tion pathways [32]. By depleting provision of 5-
methyl-tetrahydrofolate for AdoMet synthesis, the
Udali et al. Clinical Epigenetics  (2015) 7:43 Page 9 of 13SHMT1 gives higher metabolic priority to the thymi-
dylate than AdoMet biosynthesis [32]. Thus, one can
speculate that the SHMT1 repression by DNA methy-
lation depletes the AdoMet synthesis and eventually
maintains a lower DNA methylation, a universal find-
ing in cancer [7]. Other genes involved in one-carbon
metabolism were found transcriptionally repressed in
HCC tissue, although the methylation pattern was
unchanged in BHMT1, BHMT2, CBS, GNMT, and
MTHFD2L in cancer as compared to cancer-free tissue
(Additional file 3: Table S3) or decreased in FOLH1
(Table 5). All these genes exert their activity at differ-
ent crucial nodes of the methyl unit transfer pathway
for biological methylation [33]. Indeed, through this
analysis, it is not possible to clarify whether the disre-
gulation of one-carbon metabolism genes by promoter
methylation is a cause or a result of hepatocarcinogen-
esis. Nevertheless, data are in accordance with the
alcohol-induced alterations of methyl transfer reac-
tions known to have a role in alcohol-related HCC [3]
and, remarkably, show that such alterations are
reflected in significant changes in promoter DNA
methylation signature patterns in HCC tissue related
to alcohol exposure. Among the hypermethylated-
repressed genes, there was HAMP, the gene encoding
for hepcidin, a liver peptide hormone involved in iron
homeostasis and immune response [34]. HAMP has
been shown to be transcriptionally repressed in HCC
[35] and in the liver of alcoholics [36]. The transcrip-
tional repression of HAMP by promoter DNA methy-
lation in alcohol-related HCC is a novel, intriguing
finding.
Several hypomethylated and transcriptionally activated
genes were also detected in the present study. Of inter-
est is the finding of overexpression of NOX4, SPINK1,
and ESM1 epigenetically regulated by promoter methyla-
tion. The increased expression of those genes has been
previously observed in HCC for their implication in
oxidative stress defense, regulation of tumor growth,
and angiogenetic processes [37-39]. The observation
of the hypermethylated-repressed and hypomethylated-
upregulated genes confirmed the conventional notion
for the role of DNA methylation at promoter for tran-
scriptional complex regulation [40]. More uncertain is
the significance of upregulation of hypermethylated
genes and gene repression in hypomethylated genes,
even though such phenomena were previously reported
[7,8]. As it refers to hypermethylated and induced
genes, it is well known that methylation of CpG sites
blocks the binding of regulatory proteins, resulting in
transcription modulation [41]. This mechanism may
imply that hypermethylation in a silencer region could
determine an increase in gene expression by prevent-
ing the binding of a putative repressor. In a study on amurine model, we observed a positive correlation be-
tween p16 promoter methylation and p16 expression
in the old mouse colon [15,42]. The finding of hypo-
methylated and repressed genes is of more difficult
interpretation, however one could hypothesize that,
in certain genes, the regulation of transcription is in-
dependent from promoter methylation or that DNA
methylation might affect transcription by different epi-
genetic mechanisms [40].
Conclusions
In this study, a genome-wide DNA methylation ap-
proach merged with array-based gene expression profiles
allowed identifying a number of novel, epigenetically
regulated candidate tumor-suppressor genes in alcohol-
associated hepatocarcinogenesis. Moreover, retinol metab-
olism genes and SHMT1 resulted epigenetically regulated
through promoter DNA methylation in alcohol-associated
HCC.
Considering the reversibility of epigenetic mechanisms
by nutritional factors [33,43], the interest of the present
study lies precisely on the definition of promoter DNA
methylation and gene expression profiles in HCC as-
sociated to alcohol, a modifiable dietary component.
Nutrition interventional strategies may therefore be
offered for hepatic carcinogenesis prevention through
DNA methylation modulation.
Availability of supporting data
The data sets supporting the results of this article are avail-
able in the NCBI’s Gene Expression Omnibus repository
through GEO Series accession number GSE59261 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59261).
Methods
Study patients and biochemical analyses
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by
the Ethical Review Board of the University of Verona
School of Medicine Hospital (Verona, Italy). Written in-
formed consent was obtained from each patient after a
detailed explanation of the study. The key eligibility
criteria included an age ≥18 years, a diagnosis of histo-
logically confirmed HCC in patients referring to the
Divisions of Surgery and Internal Medicine. Surgical re-
sectability criteria were a preserved liver function, Child-
Pugh class A, the presence of a resectable single tumor
or oligofocal resectable nodules (maximum three nod-
ules), and the absence of extrahepatic metastases. The
resectability assessment also included the tumor local
stage, major vascular invasion, and the presence of
affected lymphonodes. Exclusion criteria included coex-
isting hepatitis B (HBV) or C virus (HCV) infections as
well as Epstein-Barr (EBV), cytomegalovirus (CMV),
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serology; presence of relevant concurrent medical con-
ditions such as chronic inflammatory diseases and
hematological disorders, including autoimmune liver
diseases and hereditary hemochromatosis, presence
of acute inflammatory diseases, decompensate liver
cirrhosis (Child-Pugh B, C). Patients under B vitamin
supplementation and/or using drugs interfering with
one-carbon metabolism in the 3 months before study
enrolment were also excluded. For preoperative sta-
ging, chest-abdomen computerized tomography (CT)
scan or nuclear magnetic resonance imaging (MRI)
was used or positron emission tomography (PET-CT)
or diagnostic laparoscopy in selected cases.
Venous blood samples were drawn from each subject
in the free-living state, for routine laboratory tests in-
cluding a complete blood count, serum concentrations
of aspartate transaminase (AST), alanine transaminase
(ALT), gamma-glutamyl transpeptidase (GGT), cholin-
esterase (CHE) and immunoglobulin (Ig) fractions in-
cluding IgA, and alphafetoprotein. Serological tests for
HBV, HCV, EBV, CMV, and HIV and tests to exclude an
autoimmune etiology of the liver disease, that is, anti-
smooth muscle, anti-nuclear, anti-mitochondrial, and
anti-liver-kidney microsomal type 1 antibodies, were
also performed. A chronic alcohol-drinking condition
was defined as the intake of ≥36 g ethanol/day for the
male sex, according to the guidelines of Italian INRAN
(Istituto Nazionale di Ricerca per gli Alimenti e
la Nutrizione, National Institute for the Research on
Foods and Nutrition). HCC tissue and cancer-free liver
tissues were excised during the surgical procedure and
analyzed for histology by a pathologist unaware of the
patient inclusion into the study. Among 33 patients
enrolled for curative surgical resection for HCC, eight
male patients were evaluated for epigenetic analyses
based on availability of all biochemical data, adequate
liver specimens with confirmed unequivocal HCC
diagnosis and homologous cancer-free liver tissue, and
a clear history of alcohol-drinking habit.
DNA and RNA extraction
After surgical excision, tissue samples for nucleic acid
extraction were immediately sliced into aliquots of about
100 mg, snap-frozen in liquid nitrogen, and stored
at −80°C until use. Aliquots for DNA extraction were
homogenized in 2 ml of chilled NaCl 0.9% w/v; cell lysis
was achieved by using Igepal CA-630 (Sigma-Aldrich,
St. Louis, MO, USA) 0.1% and lysis solution (NaCl
100 mM, EDTA 25 mM, SDS 1.6%, pH 8). Samples were
treated with proteinase K/RNase, and DNA was ex-
tracted with a standard phenol/chloroform procedure.
For RNA extraction, each liver tissue aliquot (100 mg)
was kept on ice, immediately homogenized in 2 ml ofTRIReagent® (Sigma-Aldrich, St. Louis, MO, USA) and
the homogenate stored at −80°C until use. RNA was ex-
tracted by guanidinium thiocyanate-phenol-chloroform-
based method using TRIReagent® (Sigma-Aldrich, St.
Louis, MO, USA) following manufacturer’s protocol, and
the integrity was assessed by 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). RNA samples were used in
array-based gene expression analysis only when the
RNA Integrity Number was ≥7. Nucleic acid concentra-
tion and purity were assessed by NanoDrop 1000 spec-
trophotometer (Thermo Fisher Scientific, Wilmington,
DE, USA).
MeDIP-chip analysis
The methylated DNA immunoprecipitation (MeDIP)
was performed with MeDIP kit™ (Diagenode, Liège,
Belgium) [44,45] following the manufacturer’s protocol.
After optimization of the fragmentation procedure: gen-
omic DNA was sheared by nebulization using the GS
Nebulizers Kit (Roche Applied Science, Basel, Switzerland)
with argon pressure of 3.5 bar for 1 min, achieving uni-
form DNA fragments ranging from 300 to 1,000 bp in
size, as confirmed by 2100 Bioanalyzer (Agilent, Santa
Clara, CA, USA). A 1 μg of fragmented DNA was dena-
tured (95°C for 7 min), then a one-fifth aliquot was drawn
as untreated control (non-immunoprecipitated, INPUT);
the remaining sample (immunoprecipitated, IP) was incu-
bated overnight with anti-5methyl cytidine antibody. Im-
munoprecipitation enrichment was checked by RealTime
PCR (7500 Real-Time PCR System, Applied Biosystems
by Life Technologies, Carlsbad, CA, USA) with SYBR
Green as fluorophore, both on internal and external con-
trols supplied with the MeDIP kit™ (Diagenode, Liège,
Belgium). Internal controls were human genomic regions
either methylated (X-linked α satellites, AlphaX1) or
unmethylated glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), while external controls were DNA specimens
totally methylated or totally unmethylated that were added
to the sample prior to the immunoprecipitation reaction.
IP and INPUT samples were amplified by GenomePlex
Complete Genome Amplification (WGA) kit (Sigma-Al-
drich, St. Louis, MO, USA) following the producer’s
protocol. A 1.5 μg of IP and 1.5 μg INPUT samples were
labeled with Cy5 and Cy3 respectively by Dual-Color
DNA Labeling Kit (NimbleGen-Roche, Madison, WI,
USA) and co-hybridized on the Human DNA Methylation
3x720K CpG Island Plus RefSeq Promoter Array
(NimbleGen-Roche). The microarray contained 22,532
promoters of RefSeq genes; each promoter region,
ranging from −2.44 kb to +0.61 kb from the transcrip-
tion start site, was covered by 50-75-mer probe 100 bp
spacing (all coordinates are for genome build NCBI
Hs36.3/HG18). The arrays were scanned at 2.5-μm
resolution on a Axon GenePix 4400A scanner (Axon
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cence intensity raw data were obtained by means of
Nimblescan 2.5 extraction software (NimbleGen-Roche,
Madison, WI, USA).
Gene expression analysis by microarrays
The gene expression analysis was performed by means
of Human Gene Expression 12x135K Arrays (Nimble-
gen-Roche, Madison, WI, USA) that analyzed 45,033
target genes with 60-mer probes (three probes/target),
following the producer’s procedure. Briefly, 10 μg
RNA was utilized to synthesize double-stranded cDNA
by Superscript® Double-Stranded cDNA Synthesis Kit
(Invitrogen, Carlsbad, CA, USA); 1 μg of cDNA was
labeled by One-Color DNA Labeling Kit (NimbleGen-
Roche), and 4 μg of Cy3-labeled cDNA was hybridized
on the array. The slide was scanned using the Axon
GenePix 4400A scanner, and scanned images (TIFF
format) were then imported into NimbleScan 2.5 soft-
ware for grid alignment and expression data analyses.
Validation of array-based DNA methylation and gene
expression data
DNA methylation data were validated on three hyper-
methylated, namely estrogen receptor 1 (ESR1), retinol
dehydrogenase 16 (RDH16), serine hydroxymethyltrans-
ferase 1 (SHMT1), and one hypomethylated gene, that is,
endothelial cell-specific molecule 1 (ESM1) by direct bi-
sulfite sequencing. Bisulfite treatment was performed
using the EpiTect® Bisulfite Kit (QIAGEN, Germantown,
MD, USA). For each gene, the differentially methylated
regions of interest (ROIs) were amplified by ad hoc-de-
signed primers and optimized PCR conditions. The PCR-
products were purified by GenEluteTM PCR Clean-UP kit
(Sigma-Aldrich, St. Louis, MO, USA) and then sequenced
by Capillary Electrophoretic Nucleic Acid Sequencer CEQ
8800 (Beckman Coulter, Brea, CA, USA). Gene expression
results were validated on seven repressed and four induced
genes: alcohol dehydrogenase 6 (ADH6), beta-carotene
oxygenase 2 (BCO2), ESR1, growth differentiation factor 2
(GDF2), hepcidin antimicrobial peptide (HAMP), RDH16,
SHMT1 and DNA (cytosine-5-)-methyltransferase 3 beta
(DNMT3B), ESM1, NADPH oxidase 4 (NOX4), serine pep-
tidase inhibitor, and Kazal type 1 (SPINK1), respectively by
RealTime RT-PCR using TaqMan assays. The 18S rRNA
was used as the endogenous control [46].
Computational and statistical methods
MeDIP-chip raw data were analyzed by Batman pro-
gram [47], a cross-platform algorithm (https://github.com/
dasmoth/batman) under the GNU Lesser General Public
License that permits to calculate absolute methylation
values. In the Batman analysis, the tissue samples, distin-
guished in HCC and cancer-free hepatic tissues, wereconsidered as biological replicates. The promoter region of
each gene was subdivided in 500 bp-long ROI, and an ab-
solute methylation value was associated to each ROI. A
ROI was considered differentially methylated when the dif-
ference of absolute methylation values between HCC and
cancer-free tissue was ≥30% [48]. Expression data were
normalized through quintile normalization and the Robust
Multichip Average (RMA) algorithm [49] included in the
NimbleScan software. Statistical analysis on gene expres-
sion array-based results was performed with Limma R
package [50] considering a log2-fold change ≥1 or ≤ −1
and a P value adjusted for multiple testing (FDR) ≤0.05 as
threshold to define differentially expressed genes. Protein
ANalysis THrough Evolutionary Relationship (PANTHER)
classification system was utilized to cluster genes of inter-
est on the basis of their biological process involvement
[51]. Bisulfite sequencing methylation data were obtained
by calculating a methylation index for the CpG sites
present in the ROI of each gene, as previously reported
[52]. Gene expression data obtained by RealTime RT-PCR
were analyzed by evaluating the difference in mRNA levels
between cancer and cancer-free tissue. The calculation for-
mula was the following: ΔΔCt = (Cttarget-Ct18s)HCC − (Cttar-
get-Ct18s)cancer-free.Additional files
Additional file 1: Table S1. Hypermethylated genes in HCC tissue:
2,399 genes found hypermethylated in HCC as compared to
cancer-free tissue.
Additional file 2: Table S2. Hypomethylated genes in HCC tissue: 1,243
genes found hypomethylated in HCC as compared to cancer-free tissue.
Additional file 3: Table S3. Repressed genes in HCC tissue: 1,524
transcripts corresponding to 1,004 repressed genes in HCC as compared
to cancer-free tissue (p.value.adj < 0.05).
Additional file 4: Table S4. Induced genes in HCC tissue: 1,027
transcripts corresponding to 668 induced genes in HCC as compared to
cancer-free tissue (p.value.adj < 0.05).
Additional file 5: Figure S1. Validation of DNA methylation results:
bisulfite Sanger sequencing of four differentially methylated genes in
HCC and cancer-free liver tissue.
Additional file 6: Figure S2. Validation of gene expression results:
RealTime RT-PCR data of seven repressed and four induced genes in
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